Melina Cioffi Biography and Net Worth

Dr. Cioffi joined our Company in August 2020 as our Vice President of Regulatory Affairs and leads Regulatory Affairs at the Company. She is a dedicated Regulatory Affairs expert with over 20 years of experience in the pharmaceutical industry. With deep expertise in multiple therapeutic areas including psychiatry, neurology, allergy, and immunology, Dr. Cioffi has successfully led numerous interactions with FDA, transforming regulatory challenges into opportunities for organizational growth. Prior to joining us, Dr. Cioffi held leadership positions at Axsome Therapeutics as Head of Regulatory Affairs and Forest Laboratories (now Allergan) as Director of Regulatory Affairs. Prior to Forest Laboratories she held regulatory positions at Sunovion Pharmaceuticals (now Sumitomo Pharma) and Novartis. Dr. Cioffi earned a Doctorate degree in Pharmacy from the University of the Sciences in Philadelphia and completed a Post-Doctoral Pharmaceutical Industry Fellowship with Rutgers University, Ernest Mario School of Pharmacy.

What is Melina Cioffi's net worth?: The estimated net worth of Melina Cioffi is at least $1.07 million as of March 10th, 2026. Cioffi owns 274,867 shares of Aquestive Therapeutics stock worth more than $1,066,484 as of March 24th. This net worth evaluation does not reflect any other assets that Cioffi may own. Learn More about Melina Cioffi's net worth.
How do I contact Melina Cioffi?: The corporate mailing address for Cioffi and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Melina Cioffi's contact information.
Has Melina Cioffi been buying or selling shares of Aquestive Therapeutics?: Over the course of the past ninety days, Melina Cioffi has sold $105,546.87 of Aquestive Therapeutics stock. Most recently, Melina Cioffi sold 25,311 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $105,546.87. Following the completion of the sale, the senior vice president now directly owns 274,867 shares of the company's stock, valued at $1,146,195.39. Learn More on Melina Cioffi's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Melina Cioffi Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Sell	25,311	$4.17	$105,546.87	274,867

Melina Cioffi Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61